Quick Answer
Phathom Pharmaceuticals, Inc. reported Total Assets of $259.15 million for the year ending 2025.
- Phathom Pharmaceuticals, Inc. showed a decrease of -31.5% in Total Assets from 2024 to 2025.
- This data is from Phathom Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $79.71 million | Q1 2020: $263.92 million | Q2 2020: $252.42 million | Q3 2020: $230.89 million | Q1 2021: $246.36 million | Q2 2021: $214.58 million | Q3 2021: $228.38 million | Q1 2022: $149.05 million | Q2 2022: $213.50 million | Q3 2022: $201.93 million | Q1 2023: $144.01 million | Q2 2023: $265.04 million | Q3 2023: $236.99 million | Q1 2024: $356.50 million | Q2 2024: $319.38 million | Q3 2024: $387.04 million | Q1 2025: $294.21 million | Q2 2025: $250.22 million | Q3 2025: $240.29 million.
- Over the full 8 years of available data (2018 to 2025), Phathom Pharmaceuticals, Inc.'s Total Assets has grown by 28,630.5%.
- Historical annual values: Fiscal year 2025: $259.15 million | Fiscal year 2024: $378.32 million | Fiscal year 2023: $413.84 million | Fiscal year 2022: $164.81 million | Fiscal year 2021: $189.43 million | Fiscal year 2020: $295.11 million | Fiscal year 2019: $257.18 million | Fiscal year 2018: $902.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: